What was the primary driver of the significant increase in net sales?

The primary driver of the 56% increase in net sales to $4.7 billion was the inclusion of sales from the acquired Organon BioSciences N.V. (OBS) business, which contributed $1.3 billion to the quarter's revenue. Organic growth in other segments also contributed.

Why did net income decrease so sharply despite higher sales?

The sharp decrease in net income, from $565 million to $291 million, was primarily due to significant non-cash expenses related to the acquisition of Organon BioSciences N.V. (OBS). These included costs associated with purchase accounting and integration efforts, which negatively impacted net income by $621 million in the reported quarter.

What is the impact of the ENHANCE clinical trial results on the company's business?

The ENHANCE clinical trial results and subsequent media scrutiny have negatively impacted sales of the cholesterol franchise products, VYTORIN and ZETIA, leading to a 5% decline in U.S. sales for the quarter. This has also led to increased government inquiries and litigation. The company expects lower equity income from the Merck/Schering-Plough joint venture in future quarters as a result.

What is the "Productivity Transformation Program"?

The "Productivity Transformation Program" is a new initiative announced in April 2008 aimed at creating a leaner, stronger company. It targets achieving $1.5 billion in annualized savings by 2012 through cost reduction and increased productivity, including synergies from the OBS integration.

MRK 10-Q Quarterly Report Q1 FY2008 — Revenue, Net Income, EPS

Summary

Schering-Plough Corporation (MRK) reported a net income of $291 million, or $0.15 per diluted share, for the first quarter of 2008. This represents a significant decrease from the $565 million, or $0.36 per diluted share, reported in the same period of 2007. The decline in profitability is largely attributable to substantial non-cash expenses related to the acquisition of Organon BioSciences N.V. (OBS) and integration-related activities, which impacted net income by $621 million. Despite the dip in net income, the company saw a substantial increase in net sales, reaching $4.7 billion, a 56% rise from $2.9 billion in the prior year's quarter. This growth was primarily driven by the inclusion of OBS's sales, which contributed $1.3 billion. International sales remained strong, accounting for 69% of total net sales. The company's cholesterol franchise, VYTORIN and ZETIA, experienced a 5% decline in U.S. sales, influenced by negative media attention surrounding the ENHANCE clinical trial results. Management is implementing a new "Productivity Transformation Program" aimed at cost reduction and efficiency improvements.

Key Highlights

1Net sales increased by 56% to $4.7 billion, largely due to the acquisition of Organon BioSciences N.V. (OBS).
2Net income available to common shareholders decreased significantly to $253 million from $543 million in the prior year, impacted by $621 million in purchase accounting and integration costs.
3Earnings per diluted share fell to $0.15 from $0.36 year-over-year.
4Sales from the cholesterol franchise (VYTORIN and ZETIA) declined by 5% in the U.S., attributed to scrutiny over the ENHANCE clinical trial results.
5The company announced a "Productivity Transformation Program" targeting $1.5 billion in annualized savings by 2012.
6Operating cash flow improved to $462 million from a negative $248 million in the prior year's quarter.

Merck & Co., Inc. Quarterly Report for Q1 Ended Mar 31, 2008

Summary

Key Highlights

Frequently Asked Questions